AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
7.35
+0.06 (0.82%)
Sep 10, 2026, 4:00 PM EDT - Market closed
AtaiBeckley Revenue
AtaiBeckley had revenue of $1.70M in the quarter ending June 30, 2026, with 137.00% growth. This brings the company's revenue in the last twelve months to $4.47M, up 93.68% year-over-year. In the year 2025, AtaiBeckley had annual revenue of $4.09M with 1,227.60% growth.
Revenue (ttm)
$4.47M
Revenue Growth
+93.68%
P/S Ratio
609.54
Revenue / Employee
$45,172
Employees
99
Market Cap
2.73B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.09M | 3.78M | 1,227.60% |
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 449.61M |
| Beam Therapeutics | 156.04M |
| Viridian Therapeutics | 71.13M |
| Nektar Therapeutics | 54.59M |
| Ocular Therapeutix | 52.06M |
| Nurix Therapeutics | 36.77M |
ATAI News
- 2 days ago - AtaiBeckley Transcript: EGM 2026 - Transcripts
- 24 days ago - AtaiBeckley downgraded to Perform from Outperform at Oppenheimer - TheFly
- 24 days ago - AtaiBeckley downgraded to Hold from Buy at Deutsche Bank - TheFly
- 4 weeks ago - AtaiBeckley Quarterly report: Q2 2026 - Filings
- 4 weeks ago - AtaiBeckley Proxy statement: Proxy filing - Filings
- 6 weeks ago - AtaiBeckley Proxy statement: Proxy filing - Filings
- 7 weeks ago - AtaiBeckley downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 7 weeks ago - AtaiBeckley downgraded to Hold from Buy at Berenberg - TheFly